These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
    Author: Antoniu SA, Kolb MR.
    Journal: IDrugs; 2010 May; 13(5):332-45. PubMed ID: 20432191.
    Abstract:
    Tyrosine kinase receptors have important signaling functions in various physiological and pathological pathways. The recognition of their involvement in tumor angiogenesis, which is the main event of tumor progression, opened a new era in the discovery of anticancer drugs. Developers soon grasped that by targeting several tyrosine kinase receptors at once, so-called multitarget tyrosine kinase inhibitors, a drug could dramatically affect the progression of cancer and decrease resistance. Several antiangiogenic, multitarget tyrosine kinase inhibitors, such as sorafenib and sunitinib, are already marketed, while many more are undergoing clinical trials for a range of cancer types. Boehringer Ingelheim Corp is developing intedanib (BIBF-1120), a triple kinase inhibitor blocking VEGFR, PDGFR and FGFR for the treatment of several malignancies and idiopathic pulmonary fibrosis. The preliminary data for intedanib appears at least as good as that for other antiangiogenic tyrosine kinase inhibitors or other antiangiogenic approaches that are not targeting the tyrosine kinases. The sustained inhibition of VEGFR phosphorylation (> 24 h), the fast in vivo clearance and clinical efficacy against a broad range of malignancies appear to be the major advantages of intedanib. Furthermore, the existing data suggest an excellent safety profile. At the time of publication, intedanib had reached phase III trials for the treatment of NSCLC and ovarian cancer.
    [Abstract] [Full Text] [Related] [New Search]